Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on MATOMY MEDIA GROUP LTD. We currently have 2 research reports from 2 professional analysts.
|03Feb17 13:21||RNS||MMG- Block Listing & Update on Total Voting Rights|
|19Jan17 12:01||RNS||Matomy-Appointment of Chairman and Deputy Chairman|
|13Jan17 07:21||RNS||Partial Option Exercise - Team Internet AG Shares|
|11Jan17 10:28||RNS||Matomy Media Group - Result of EGM|
|22Dec16 16:54||RNS||MMG- AMENDMENT TO FORMS OF PROXY AND INSTRUCTION|
|05Dec16 09:09||RNS||Notice of AGM and Board Changes|
|08Nov16 15:13||RNS||Total Voting Rights|
Frequency of research reports
Research reports on
MATOMY MEDIA GROUP LTD
MATOMY MEDIA GROUP LTD
Panmure Research - Media Flash 06-10-15
06 Oct 15
US dollar strength has contributed to yet another strong week for UK media: year to date, the sector is now 14% ahead of the market. The key USD earners to miss out on this trend last week were Entertainment One (acquisition of Astley Baker Davies and rights issue) and Euromoney (emerging market and investment banking concerns). Rightmove had a weaker week, but remains the top performer in the sector on a year to date basis. In contrast Entertainment One is now down over 20% year to date, with valuation now down to 8.8x EPS and 7.5x EBITDA for Mar17E (based on consensus forecasts).
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
N+1 Singer - Morning Song 23-02-2017
23 Feb 17
Genus (GNS LN) Interim results: R&D step-up, disappointing ABS performance | Howden Joinery Group (HWDN LN) Prelims and net cash better than expected but conditions weaken | Oxford Pharmascience Group (OXP LN) Encouraging interim OXPzero™ Ibuprofen exploratory PK data | StatPro Group (SOG LN) Increased majority shareholding in Infovest Consulting | Wilmington Group (WIL LN) Interims slightly ahead, move to focus on 3 verticals
N+1 Singer - Small-cap quantitative research - New quality style screen + 11 quality focus stocks
09 Feb 17
We introduce our fourth and final style screen representing “quality”. This screens for stocks with the best combination of high returns on capital/equity, EBIT margins and operating cash-flow conversion rates. These criteria should help us monitor how strong underlying returns translate into share price performance over time and under varying market conditions. The screen selects the “best” 25 stocks from our universe of just over 500 stocks and, as usual, we focus on a shorter list of stocks we cover or otherwise know and believe to be particularly interesting. We provide brief investment summaries on these focus stocks on pages 4 – 9. We will monitor performance and refresh the screen in approximately 3-4 months time.
Another positive financial performance in FY16
23 Feb 17
As expected, RELX produced satisfactory FY 16 results, with organic revenue growth positively accelerating to +4% (FY15 at +3%). Consolidated revenues reached £6,895m (+15%) after a total forex impact of +11%, reflecting the weakness in sterling versus both the US dollar and euro (only 7.3% of sales in the UK). The group’s adjusted OP amounted to £2,114m, up 6% organically (+16% reported) and reflecting an improving margin to 30.7% from 30.5% in FY15, although slightly under our 31% expectation. The adjusted EPS increased by 8% at CER to 72.2p (AV: 71.8p). The full-year dividend is raised 21% to 35.95p (AV at 34.8p) after a final at 25.7p from 22.3p a year earlier (as a reminder, the group had announced in August a larger than usual interim dividend primarily due to end-period forex). RELX announced a new £700m share buy-back programme for FY17e (£100m completed so far) after £700m completed in FY16 and is confident to deliver in FY17e “another year of underlying revenues, profit and earnings growth”, a positive statement although as vague as usual.
Solid organic growth and significant improvement in profitability
22 Feb 17
Wolters Kluwer reported FY16 revenues of €4,297m, up 2% and in line with our forecast of €4,300m (+3% organically, i.e. positively accelerating from the +2% in the first 9 months, and similar to FY15) as well as a 22.1% adjusted operating margin, up 70bp from 21.4% a year earlier and slightly above expectations (as a reminder the group’s guidance was for between 21.5% and 22%; AV’s was 21.6%). This was after restructuring expenses of €29m. The adjusted net profit was €618m, above our €604m expectations, i.e. diluted adjusted EPS of €2.10, up 7% and versus our €2.04. The group generated a solid €708m FCF in FY16, up 9% at CER and ended the year with a strong financial position (net debt/EBITDA ratio of 1.7x). The proposed FY16 total dividend is up 5% to €0.79/share.